Genaissance Pharmaceuticals (GNSC) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Genaissance Pharmaceuticals (GNSC)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Jim Oravetz who started this subject	9/25/2002 9:51:44 PM
From: Findit	Read Replies (1) of 183

Some GNSC commentary from RB - >>I got into GNSC at what I thought was rock bottom (~1buck) and am surprised/disappointed to be where we are now. However I got into gnsc because, despite what many people on this board might have to say, the scientific approach that gnsc has pioneered (that is the mass cataloguing of human haplotypes) is a potentially very powerful and fruitful enterprise. I'm an academic scientist working on the pharmacogenomics of asthma and cardiac illness, and over the last year we have shifted most of our clinical association studies from SNP based studies (single variations) to haplotype based studies (examination of more than one variation at once). Over the past year or so I've seen a shift in attitude of many of the research teams working in this area, and it seems the general feeling now regarding most pharmacogenetic analyses, is that single SNP studies are no longer comprehensive enough to tease out the real effects of genetics in drug treatment. This attitude is reflected by the type of results that we and others are now generating regarding haplotype based association studies, and one only has to visit any large human genetics conference to see that haplotyping is becoming the gold standard in not only pharmacogenetic but other disease-associated analyses. Haplotyping is the most comprehensive way to read the variation in our genes and gnsc owns and continues to build the most comprehensive database of this information. Without being overly optimistic, would it be reasonable to assume that shares in such a company would be worth more than 50 cents? I think so. Bottom fishing anyone? ARRAYTHEWAY<<

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next